Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06940739 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
A Phase 1 study of Metastatic Melanoma and Unresectable Melanoma, sponsored by Iovance Biotherapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
- 4
- Study locations
NCT06940739 is a Phase 1 study of Metastatic Melanoma and Unresectable Melanoma that is actively recruiting participants, run by Iovance Biotherapeutics. The registered enrollment target is 42 participants, below the 83-participant average among 91 other Metastatic Melanoma trials with a reported enrollment target (49% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT06940739, a Phase 1 study of Metastatic Melanoma and Unresectable Melanoma, is actively recruiting participants, sponsored by Iovance Biotherapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
- 4
- Study locations
Study Summary
A Phase 1/2, open-label study of a modified interleukin-2 fusion protein (IOV 3001) in participants with previously treated, unresectable or metastatic melanoma who will receive lifileucel.
Conditions Studied
Interventions
- BIOLOGICAL IOV-3001
Study Locations (4)
Colorado
- SCRI Oncology Partners- Denver - Denver
North Carolina
- UNC Hospitals, The University of North Carolina at Chapel Hill - Chapel Hill
Tennessee
- Sarah Cannon Research Institute - Nashville
Queensland
- Greenslopes Private Hospital - Greenslopes
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2025-03-11 |
| Est. Completion | 2032-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06940739
The ClinicalTrials.gov registry entry for NCT06940739 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 83-participant average among 91 other Metastatic Melanoma trials with a reported enrollment target (49% lower). The listed sponsor is Iovance Biotherapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Metastatic Melanoma appearing as the primary indexed condition, and to 1 intervention - of which IOV-3001 is the first listed.
NCT06940739 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Colorado, North Carolina, Tennessee.
Frequently Asked Questions
What is clinical trial NCT06940739 about?
NCT06940739 is a clinical study titled "A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel". A Phase 1/2, open-label study of a modified interleukin-2 fusion protein (IOV 3001) in participants with previously treated, unresectable or metastatic melanoma who will receive lifileucel.
What is the current status of trial NCT06940739?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2025-03-11. Estimated completion is 2032-07.
What conditions does trial NCT06940739 study?
This clinical trial studies the following conditions: Metastatic Melanoma, Unresectable Melanoma, Ocular Melanoma.
What interventions are being tested in trial NCT06940739?
The interventions under investigation include: IOV-3001 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06940739?
This trial is sponsored by Iovance Biotherapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06940739 being conducted?
This trial has 4 study locations across Colorado, North Carolina, Tennessee, Queensland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
RECRUITING · Phase 1
-
Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma
RECRUITING · Phase 1
-
Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma
RECRUITING · Phase 1
-
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma
RECRUITING · Phase 1
-
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
RECRUITING · Phase 1
-
Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.